India

MSF responds to USTR 2020 Special 301 Report

Intellectual property and trade Press release United States of AmericaIndia

Amidst the ongoing global crisis caused by the COVID-19 pandemic, the United States Trade Representative (USTR) released its annual “Special 301 Report” targeting countries for implementing and supporting public health safeguard in their intellectual property laws and policies. In the 2020 report, countries like India, Brazil, China, Chile and Canada, have faced unwarranted pressure from the United States Government for measures adopted by them to ensure access to medicines. 

4

MSF submission to USTR 2020 Special 301 Report review process

On 6 February 2020, Médecins Sans Frontières (MSF) submitted comments to the United States Trade Representative (USTR) for its 2020 Special 301 review process, raising concerns of the public health impact of this process. The Special 301 Report hampers the ability of countries to ensure the protection of public health and promotion of access to medicines.

MSF recommends that the USTR refrain from listing countries on the Special 301 "watch lists" for making use of safeguards available under the Trade Related Aspects of Intellectual Property (TRIPS) Agreement to promote access to medicines.

United States of AmericaIndia Intellectual property and trade Statement
MSF Pharmacy Technician Toueng Sreymon distributes Hepatitis C meds at the MSF Hepatitis C clinic at Preah Kossamak Hospital in Phnom Penh, Cambodia, 18, April 2017. Photograph by Todd Brown Photograph by Todd Brown

The USTR called for comments from stakeholders for their 2020 Special 301 Report. The Special 301 Report is an annual report by the USTR that names countries on "watch lists" in line with its powerful pharmaceutical industry's demands that governments not make use of public health safeguards in intellectual property and regulatory laws.

Off

The USTR called for comments from stakeholders for their 2020 Special 301 Report. The Special 301 Report is an annual report by the USTR that names countries on "watch lists" in line with its powerful pharmaceutical industry's demands that governments not make use of public health safeguards in intellectual property and regulatory laws.    

0
center

MSF urges PM Modi not to make any trade commitments to US threatening access to medicines

Intellectual property and trade Press release United States of AmericaIndia

“India should be cautious while signing any trade package or launching trade negotiations with the US that may include harmful provisions threatening India’s ability to produce and supply affordable medical products. Going by past practises, the key focus of the US in any trade pact has always been to prioritise the interests of its pharmaceutical corporations at the cost of people lives.

The world can’t afford to see India’s pharmacy shut down to protect the profiteering of U.S. pharmaceutical corporations.”

2

TB survivors challenge J&J's patent on TB drug in India

Tuberculosis Video India

Phumeza and Nandita suffered permanent hearing loss because of toxic drugs used to treat their drug-resistant TB.

Now they’re working to ensure that this doesn’t happen to anyone else.

1

TB activists for first time challenge TB drug patent in India

Tuberculosis Press release India

Médecins Sans Frontières (MSF) is supporting a patent challenge filed in India this week by two tuberculosis survivors, to prevent pharmaceutical corporation Johnson & Johnson (J&J) from extending its monopoly on the tuberculosis drug bedaquiline.

6
Subscribe to India